Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES014 in Advanced Solid Tumors
NCT06543056Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, Fc Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ES014 in malignant pleural mesothelioma (MPM), myxofibrosarcoma (MFS), malignant peripheral nerve sheath tumor (MPNST) and 1 more, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Evaluating the Efficacy of ES014 in Adult Subjects with Advanced Solid Tumours. Started Nov 2024; status: recruiting.
02
Drugs
ES014
03
Conditions
malignant pleural mesothelioma (MPM)myxofibrosarcoma (MFS)malignant peripheral nerve sheath tumor (MPNST)solid tumor
Beyond the preview
Go deeper on NCT06543056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06543056.